NSD1 and synovial sarcoma: We identified 7,085 CpG sites distributed across the genome that we refer to as the NSD1+/−-specific signature; 7,038 CpG sites (99.3%) demonstrated loss of DNAm (Supplementary Data 3), whereas only 47 CpG sites (0.7%) showed a gain of DNAm in SS compared with controls.